Efficacy and safety of mirabegron, a β
            3
            ‐adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility

Cheng‐Ling Lee; Hann‐Chorng Kuo

doi:10.1111/luts.12224

Efficacy and safety of mirabegron, a β 3 ‐adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility

LUTS Lower Urinary Tract Symptoms ◽

10.1111/luts.12224 ◽

2018 ◽

Vol 11 (2) ◽

pp. O93-O97 ◽

Cited By ~ 5

Author(s):

Cheng‐Ling Lee ◽

Hann‐Chorng Kuo

Keyword(s):

Efficacy And Safety ◽

Adrenoceptor Agonist ◽

Detrusor Hyperactivity

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793482011 ◽

2013 ◽

Author(s):

Francisco Cruz

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793480560 ◽

2013 ◽

Author(s):

Howard Goldman ◽

Alana M Murphy

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

MP87-06 THERAPEUTIC EFFICACY AND SAFETY OF SHIFTING FROM ANTIMUSCARINICS TO BETA-3 ADRENOCEPTOR AGONIST – WHICH PATIENTS BENEFIT MOST FROM THE CHANGE?

The Journal of Urology ◽

10.1016/j.juro.2016.02.2356 ◽

2016 ◽

Vol 195 (4S) ◽

Author(s):

Chun-Hou Liao ◽

Hueih-Ling Ong ◽

Hann-Chorng Kuo

Keyword(s):

Therapeutic Efficacy ◽

Efficacy And Safety ◽

Adrenoceptor Agonist

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793480637 ◽

2013 ◽

Author(s):

Alexander Roosen

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

Faculty of 1000 evaluation for A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718020708.793480105 ◽

2013 ◽

Author(s):

Altaf Mangera

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study

LUTS Lower Urinary Tract Symptoms ◽

10.1111/luts.12053 ◽

2014 ◽

Vol 7 (2) ◽

pp. 84-92 ◽

Cited By ~ 15

Author(s):

Osamu YAMAGUCHI ◽

Eiji MARUI ◽

Yasuhiko IGAWA ◽

Masayuki TAKEDA ◽

Osamu NISHIZAWA ◽

...

Keyword(s):

Overactive Bladder ◽

Japanese Patients ◽

Dose Finding ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Adrenoceptor Agonist ◽

Finding Study ◽

Dose Finding Study

Download Full-text

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection in Patients with Detrusor Hyperactivity and Impaired Contractility

Toxins ◽

10.3390/toxins8030082 ◽

2016 ◽

Vol 8 (3) ◽

pp. 82 ◽

Cited By ~ 11

Author(s):

Chung-Cheng Wang ◽

Cheng-Ling Lee ◽

Hann-Chorng Kuo

Keyword(s):

Efficacy And Safety ◽

Detrusor Hyperactivity

Download Full-text

Faculty Opinions recommendation of A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020708.793480916 ◽

2013 ◽

Author(s):

Sanjay Kulkarni ◽

Pankaj Joshi

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Urology ◽

10.1016/j.urology.2013.02.077 ◽

2013 ◽

Vol 82 (2) ◽

pp. 313-320 ◽

Cited By ~ 149

Author(s):

Sender Herschorn ◽

Jack Barkin ◽

David Castro-Diaz ◽

Jeffrey M. Frankel ◽

Montserrat Espuna-Pons ◽

...

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive Bladder

Yearbook of Urology ◽

10.1016/j.yuro.2014.03.003 ◽

2014 ◽

Vol 2014 ◽

pp. 68-69

Author(s):

E.S. Rovner

Keyword(s):

Overactive Bladder ◽

Multicentre Study ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Adrenoceptor Agonist ◽

Parallel Group

Download Full-text